Nachrichten zur Cara Therapeutics Aktie

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to…

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a…

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company…

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary…

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company…

CDTX INVESTOR ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX

NEW YORK, May 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a…

CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company…

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company…

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a…

Erste Schätzungen: Cara Therapeutics öffnet die Bücher zum abgelaufenen Quartal

Cara Therapeutics präsentiert voraussichtlich am 04.03.2024 die Bilanzzahlen zum am 31.12.2023 beendeten Jahresviertel.Im Schnitt gehen 5 Analysten von einem Verlust…

Cara Therapeutics to report full year results on March 4 By Investing.com

Cara Therapeutics to report full year results on March 4…

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host…

Premier Diversified Holdings Inc. Announces Cease Trade Order and Provides Update on the Proposed Acquisition of AJA Health and Wellness Ltd., Assured Diagnosis Inc., and AJA Therapeutics Inc.

Not for dissemination in the United States of America…

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a…

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies…

Carmot Therapeutics Announces Completion of Acquisition by Roche

BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to…

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a…

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

SAN DIEGO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate)…

$KRTX | Karuna Therapeutics Inc. ($$KRTX) Trading Report (KRTX)

Buy Karuna Therapeutics Inc. ($KRTX) slightly over 212.68 target n/a stop loss @ 212.07. Details…

CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results

SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company…

Roche Acquiring Obesity Drug Maker Carmot for $3.1 Billion

Roche Holding AG will pay as much as $3.1 billion for Carmot Therapeutics Inc., in a deal that includes three…

Merck to acquire Caraway Therapeutics for up to $610M

Merck & Co Inc announced on Tuesday an agreement to acquire Caraway Therapeutics Inc for a total potential consideration of up…

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on…

Erste Schätzungen: Cara Therapeutics präsentiert Quartalsergebnisse

Cara Therapeutics gibt voraussichtlich am 13.11.2023 die Zahlen für das am 30.09.2023 abgelaufene Quartal bekannt.Die Schätzungen von 6 Analysten belaufen…

Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

DOYLESTOWN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a…

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its…

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary…

Premier Diversified Holdings Inc. Announces Letter of Intent for Acquisition of AJA Health and Wellness Ltd., Assured Diagnosis Inc., and AJA Therapeutics Inc.

Not for dissemination in the United States of America…

dpa-AFX ProFeed